Pharmacokinetic study of colistimethate sodium

2024-520019-41-00 Human pharmacology (Phase I) - Other Ended

Start 30 Jun 2025 · End 20 Jul 2025 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 56
Countries 1
Sites 1

serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options

Key facts

Sponsor
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01]
Trial duration
30 Jun 2025 → 20 Jul 2025
Decision date (initial)
2025-04-24
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options

VersionLevelCodeTermSystem organ class
20.0 SOC 10038738 Respiratory thoracic and mediastinal disorders 13

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Tarchominskie Zaklady Farmaceutyczne Polfa S.A.

Sponsor organisation
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Address
Ul. Aleksandra Fleminga 2
City
Warsaw
Postcode
03-176
Country
Poland

Scientific contact point

Organisation
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Contact name
Ilona Łojszczyk, PhD Eng.

Public contact point

Organisation
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Contact name
Ilona Łojszczyk, PhD Eng.

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 56 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinic, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-06-30 2025-07-20 2025-06-30 2025-07-12

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-04 Czechia Acceptable
2025-04-23
2025-04-24
2 SUBSTANTIAL MODIFICATION SM-1 2025-05-15 Czechia Acceptable
2025-05-30
2025-05-30